Concord Biotech's Limbasi facility clears Brazilian regulator ANVISA inspection

12 Jun 2026via NSE FilingSource

English हिंदी తెలుగు தமிழ்ಕನ್ನಡ मराठी বাংলা ગુજરાતી

Concord Biotech's Limbasi API facility has passed the ANVISA inspection by Brazil’s health regulator. This clearance is a positive step toward potential market access in Brazil. Regulatory approvals like this enhance export prospects and validate manufacturing standards. 📊 STOCKS: CONCORDBIO | 🏢 SECTOR: Pharma | #MEDIUMIMPACT #RegulatoryUpdate

#RegulatoryUpdate#ANVISA#API

Stocks mentioned

CONCORDBIOCONCORDBIO

⚠️ This brief is AI-generated from public news sources for informational purposes only. Not investment advice. Always consult a SEBI-registered advisor before trading.

Trade smarter on NSE

Live option chains, FII flows, PCR, AI analysis — for NIFTY, BANKNIFTY & 200+ F&O stocks.

Start for ₹1 →